BioCentury

8:00 AM GMT, Jan 16, 2012
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Strategy

Karo Bio's next act

Karo Bio AB thinks its deal with Pfizer Inc. will change the common perception that the company has nothing of value but eprotirome.

Eprotirome, a thyroid hormone receptor agonist, is in the Phase III AKKA trial in 630 patients with heterozygous familial hypercholesterolemia (HeFH). Interim three-month data from the first 150 patients are expected in 2Q12.

Last October, Karo Bio decided to spin out its preclinical operations into a subsidiary to separate them from eprotirome and to sharpen the company's focus, President and CEO Per Bengtsson told BioCentury. "It's

Read the full 877 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.